[go: up one dir, main page]

AR050215A1 - Metodo para diagnosticar enfermedades utilizando copeptina. - Google Patents

Metodo para diagnosticar enfermedades utilizando copeptina.

Info

Publication number
AR050215A1
AR050215A1 ARP050103483A AR050215A1 AR 050215 A1 AR050215 A1 AR 050215A1 AR P050103483 A ARP050103483 A AR P050103483A AR 050215 A1 AR050215 A1 AR 050215A1
Authority
AR
Argentina
Prior art keywords
copeptine
diagnosing diseases
diseases
shock
copeptin
Prior art date
Application number
Other languages
English (en)
Original Assignee
B R A H M S Aktiengelsellschaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B R A H M S Aktiengelsellschaf filed Critical B R A H M S Aktiengelsellschaf
Publication of AR050215A1 publication Critical patent/AR050215A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5757—Vasoactive intestinal peptide [VIP] or related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/15—Oxytocin or vasopressin; related peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

El uso de copeptina como marcador de diagnostico para determinar la liberacion fisiologica de vasopresina, especialmente en relacion con el diagnostico, pronostico y el monitoreo del curso de enfermedades, tales como enfermedades cardíacas, shock, incluyendo shock séptico, sepsis y diversos tipos de cáncer y tumores.
ARP050103483 2004-08-19 2005-08-19 Metodo para diagnosticar enfermedades utilizando copeptina. AR050215A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20040019732 EP1628136A1 (en) 2004-08-19 2004-08-19 Method of diagnosis of disease using copeptin

Publications (1)

Publication Number Publication Date
AR050215A1 true AR050215A1 (es) 2006-10-04

Family

ID=34926232

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103483 AR050215A1 (es) 2004-08-19 2005-08-19 Metodo para diagnosticar enfermedades utilizando copeptina.

Country Status (10)

Country Link
US (3) US7807397B2 (es)
EP (2) EP1628136A1 (es)
JP (2) JP4932714B2 (es)
CN (2) CN102539789B (es)
AR (1) AR050215A1 (es)
AT (1) ATE375518T1 (es)
DE (1) DE602005002836T2 (es)
ES (1) ES2296224T3 (es)
MX (1) MXPA06014775A (es)
WO (1) WO2006018315A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140046407A1 (en) * 2001-08-31 2014-02-13 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
DE102006034142A1 (de) 2006-07-24 2008-01-31 B.R.A.H.M.S. Aktiengesellschaft Verfahren zur Steuerung der Therapie von Patienten mit Herzinsuffizienz anhand der vitro Bestimmung von Schwellenwerten von vasoaktiven Peptiden
DE102006046996A1 (de) * 2006-10-01 2008-04-03 Brahms Aktiengesellschaft Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz
JP5855332B2 (ja) * 2006-10-18 2016-02-09 アクセラ インコーポレーテッド 広い濃度範囲にわたる複数アナライトの光回折による測定
ES2652027T3 (es) * 2006-10-26 2018-01-31 B.R.A.H.M.S. Gmbh Estratificación de riesgo del síndrome coronario agudo por medio de fragmentos / péptidos parciales de la provasopresina, en particular copeptina o neurofisina II
DE102006050497A1 (de) * 2006-10-26 2008-04-30 Brahms Aktiengesellschaft Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II
DE102006053442A1 (de) * 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II
DE102006058266A1 (de) * 2006-12-08 2008-06-12 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz mittels Neurophysin
EP2180322A1 (en) * 2008-10-22 2010-04-28 BRAHMS Aktiengesellschaft Prognostic biomarkers for the progression of primary chronic kidney disease
US9116153B2 (en) * 2008-10-31 2015-08-25 B.R.A.H.M.S Gmbh Arginine vasopressin pro-hormone as predictive biomarker for diabetes
US20100312581A1 (en) * 2009-06-08 2010-12-09 Peter James Wachtell Process and system for efficient allocation of medical resources
US20120129187A1 (en) 2009-06-16 2012-05-24 B.R.A.H.M.S. Gmbh Diagnostical use of peroxiredoxin 4
ES2676247T3 (es) * 2010-06-18 2018-07-18 B.R.A.H.M.S Gmbh Biomarcadores para la predicción de nuevos casos de cáncer
JP2014518881A (ja) 2011-05-26 2014-08-07 フェニックス ファーマシューティカルズ， インコーポレイテッド フェニキシンペプチド
EP2541252A1 (en) 2011-06-30 2013-01-02 B.R.A.H.M.S GmbH Method of obtaining a binder to prepro-vasopressin or fragments thereof
EP2776064A4 (en) 2011-11-11 2015-08-05 Woomera Therapeutics PROVASOPRESSINE ANTAGONISTS AND ITS USES
GB201210686D0 (en) * 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
JP6813503B2 (ja) 2015-02-10 2021-01-13 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング バイオマーカーとしての遊離ヒストンタンパク質
EP3279667A1 (en) 2016-08-02 2018-02-07 Abbott Laboratories Cardiac troponin i and copeptin as biomarkers for short-term mortality in acute exacerbation of chronic obstructive pulmonary disease (aecopd)
CN109061140A (zh) * 2018-08-31 2018-12-21 广州华澳生物科技有限公司 一种和肽素免疫层析检测试剂卡及其制备方法
CN109679924A (zh) * 2018-12-25 2019-04-26 广州万孚生物技术股份有限公司 高亲和力抗人和肽素的单克隆抗体及其制备方法与应用
CN109596839A (zh) * 2018-12-25 2019-04-09 广州万孚生物技术股份有限公司 人和肽素快速定量检测方法与试剂盒
JP7640168B2 (ja) * 2019-01-28 2025-03-05 ベー．エル．アー．ハー．エム．エス ゲーエムベーハー 夜尿症の患者の治療応答を予測する方法
CN111007270A (zh) * 2019-11-27 2020-04-14 迪瑞医疗科技股份有限公司 和肽素化学发光免疫检测试剂盒及其制备方法
CN113406339A (zh) * 2021-08-19 2021-09-17 山东康华生物医疗科技股份有限公司 一种干式免疫荧光定量法人和肽素（cpp）检测试剂盒

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413783B1 (en) * 1997-09-18 2002-07-02 Meso Scale Technologies, Llc Assay sonication apparatus and methodology
US6822082B2 (en) * 2000-06-30 2004-11-23 Zymogenetics, Inc. Polynucleotides for mammalian secreted protein, Z1055G2P
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
CN1166953C (zh) * 2001-05-30 2004-09-15 上海晶泰生物技术有限公司 一步法多指标检测心肌梗塞的快速金标检测试剂盒
RU2327484C2 (ru) * 2001-11-26 2008-06-27 Асубио Фарма Ко., Лтд Фармацевтическая композиция для назального всасывания
AU2003251966A1 (en) * 2002-07-16 2004-02-02 Woomera Therapeutics Inc Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells
CA2511482A1 (en) * 2002-12-24 2004-07-15 Biosite Incorporated Method and system for disease detection using marker combinations
ES2652027T3 (es) * 2006-10-26 2018-01-31 B.R.A.H.M.S. Gmbh Estratificación de riesgo del síndrome coronario agudo por medio de fragmentos / péptidos parciales de la provasopresina, en particular copeptina o neurofisina II
DE102006053442A1 (de) * 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II
DE102006060112A1 (de) * 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
DE102007010834A1 (de) * 2007-03-03 2008-09-04 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz für NYHA I Patienten

Also Published As

Publication number Publication date
HK1114171A1 (en) 2008-10-24
JP2011227095A (ja) 2011-11-10
DE602005002836D1 (de) 2007-11-22
EP1628136A1 (en) 2006-02-22
CN102539789A (zh) 2012-07-04
CN101010591A (zh) 2007-08-01
US7807397B2 (en) 2010-10-05
ES2296224T3 (es) 2008-04-16
WO2006018315A1 (en) 2006-02-23
CN102539789B (zh) 2015-04-08
DE602005002836T2 (de) 2008-07-31
US20090221009A1 (en) 2009-09-03
EP1738178B1 (en) 2007-10-10
EP1738178A1 (en) 2007-01-03
US20170242037A1 (en) 2017-08-24
JP4932714B2 (ja) 2012-05-16
MXPA06014775A (es) 2007-03-23
US20110008911A1 (en) 2011-01-13
HK1172690A1 (en) 2013-04-26
JP2008510151A (ja) 2008-04-03
ATE375518T1 (de) 2007-10-15
CN101010591B (zh) 2011-12-21

Similar Documents

Publication Publication Date Title
AR050215A1 (es) Metodo para diagnosticar enfermedades utilizando copeptina.
Ghorbani et al. Application of various optical and electrochemical aptasensors for detection of human prostate specific antigen: A review
ES2484417T3 (es) Perfil de expresión génica como marcador de la receptividad endometrial
CL2021002852A1 (es) Combinación de marcadores de microrrelieve para el diagnóstico del cáncer gástrico y kit de diagnóstico
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
EP1732602A4 (en) CYTOTOXICITY TRANSFER OF CELLS WITH NOTES ON SURFACE EXPRESSION OF MCSP
DOP2007000102A (es) Arilimidazolonas y ariltriazolona sustituidas asi como su uso
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
PE20100449A1 (es) Kit que comprende colorantes de cianina para la deteccion de enfermedades proliferativas
MX2010014228A (es) Metodos y productos de diagnostico del p/gf-1 acompañante.
GB0718967D0 (en) Peptide imaging agents
WO2006024466A3 (de) Testvorrichtung für die in vitro diagnostik von multianalyt-tests und deren verwendung
WO2009052970A3 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
FR2982369B1 (fr) Procede non invasif de detection, de visualisation et/ou de quantification 3d specifiques d'un fluorophore endogene tel la melanine au sein d'un tissu biologique.
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
WO2015081283A3 (en) Long non-coding rna as a diagnostic and therapeutic agent
WO2011093675A3 (ko) 혈액으로부터 직접 폐암 진단 및 폐암의 서브타입 진단이 가능한 마커를 선별하는 시스템 생물학적 방법 및 이로부터 선별된 혈액으로부터 직접 폐암 진단 및 폐암 서브타입 진단이 가능한 마커
ATE538811T1 (de) Zytotoxizitätsvermittlung von zellen mit hinweisen auf oberflächenexpression von cd44
BRPI0512209A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens de um corpo humano ou de animal por formação de imagem óptica, e de monitoração do efeito de tratamento de um corpo humano ou de animal com uma droga para combater uma condição associada com angiogênese
WO2010096426A8 (en) Compounds, compositions, methods of synthesis, and methods of treatment
EA201290245A1 (ru) Радиоактивно меченные pde10 лиганды
WO2005113831A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2010131193A8 (en) Phosphodiesterase 9a as prostate cancer marker
WO2007005502A3 (en) Methods and compositions for treating diseases targeting cdcp1
SG160327A1 (en) Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds

Legal Events

Date Code Title Description
FG Grant, registration